Summit Therapeutics (SMMT) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, to be held virtually, with voting on four key proposals including director elections, auditor ratification, executive compensation, and an amendment to the stock incentive plan.

• Record date for voting is April 15, 2026; shareholders can vote online, by phone, mail, or during the meeting.

• Board recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Election of nine directors to serve until the 2027 annual meeting.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory (non-binding) vote on executive compensation (say-on-pay).

• Approval of an amendment to the 2020 Stock Incentive Plan to increase authorized shares by 8,000,000.

• Shareholder proposals for the 2027 meeting must be submitted by December 18, 2026, for inclusion.

Board of directors and corporate governance

• Board consists of nine nominees, including both executive and independent directors; five are independent per Nasdaq rules.

• Robert W. Duggan serves as both Co-CEO and Chairman; Kenneth A. Clark is Lead Independent Director.

• Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent chairs.

• Directors are evaluated on integrity, business acumen, and commitment to company interests.

• Code of business conduct and insider trading policy in place.